Press release

Siemens Healthineers and Unilabs launch strategic partnership for latest diagnostic testing infrastructure to improve patients’ care

Joint Press Release by Siemens Healthineers and Unilabs 

Published on February 2, 2023
<p>Siemens Healthineers, a leading medical technology company, and Unilabs, a leading diagnostic services provider, announced today a multi-year agreement valued at over €200 million. Unilabs has invested in Siemens Healthineers top-notch technology and will acquire more than 400 laboratory analyzers to further improve its laboratory infrastructure to offer an unparalleled service to its customers.&nbsp;</p><p>“Delivering the best possible patient care is at the heart of everything we do, and we will continue to invest in the latest technology to further boost our services,” said Michiel Boehmer, Unilabs’ CEO. “Our CARE BIG mantra is driving us in our quest to build the most-digitally driven diagnostics group – enabling better decisions for a healthier tomorrow.”&nbsp;</p><p>Under this agreement, Unilabs will continue modernizing its healthcare infrastructure across its network to improve customer service and quality, and thereby improve patient health. The solutions Siemens Healthineers provides will enhance Unilabs’ laboratory operations, throughput, and clinical equivalence across its testing network.&nbsp;</p><p>In the first years, Siemens Healthineers will install high- and mid-volume immunoassay and clinical chemistry analyzers, including the Atellica Solution and Atellica CI 1900<sup>1</sup>, sample handlers, haemostasis analyzers, and automation solutions.&nbsp;</p><p>"Siemens Healthineers is uniquely positioned to add value through a portfolio of products that work in harmony to scale technology, especially as testing demand grows,” said Sharon Bracken, Head of Diagnostics for Siemens Healthineers. "Our solutions help on many levels. They can improve cost savings and profitability through integrated reagents and consumables, deliver sophisticated intelligence software for better data analytics, and reduce unnecessary workflow friction with intuitive system user interfaces. We look forward to how our collaboration with Unilabs, along with its expanded investment in Siemens Healthineers technology, will benefit the company’s laboratory operations and patient care for years to come."&nbsp;</p><p><strong>Commitment to Sustainability </strong><br>Unilabs also will partner with Siemens Healthineers to help combat climate change and save local resources. Both companies are deeply committed to sustainability.&nbsp;</p><p>“We are strongly committed to sustainability, and this partnership will also reduce our laboratories' environmental footprint by implementing Siemens Healthineers' proven technologies and methodologies,” said Dr Christian Rebhan, Unilabs’ President - Scientific Business Units and Chief Medical Officer.</p>

Download image


Siemens Healthineers 2023

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion. Further information is available at